// App-Quantinova.ai

TPS8052 : CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Researchers

Presenter

  • Sagar Lonial

Principal Investigators

  • Paul G. Richardson

  • Donna Ellen Reece

  • Hesham Mohamed

  • Suresh Shelat

  • Jesus San Miguel

Medical Centers

  • Winship Cancer Inst, Atlanta, GA

  • Dana-Farber Cancer Institute, Boston, MA

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Bristol-Myers Squibb, Lawrenceville, NJ

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, IDISNA, CIBERONC, Pamplona, Spain

Locations

  • United States

  • Canada

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Elotuzumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT02726581

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved